These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 23867518)
1. Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Finke JH; Rayman PA; Ko JS; Bradley JM; Gendler SJ; Cohen PA Cancer J; 2013; 19(4):353-64. PubMed ID: 23867518 [TBL] [Abstract][Full Text] [Related]
2. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783 [TBL] [Abstract][Full Text] [Related]
3. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626 [TBL] [Abstract][Full Text] [Related]
4. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Xin H; Zhang C; Herrmann A; Du Y; Figlin R; Yu H Cancer Res; 2009 Mar; 69(6):2506-13. PubMed ID: 19244102 [TBL] [Abstract][Full Text] [Related]
5. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097 [TBL] [Abstract][Full Text] [Related]
6. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models. Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449 [TBL] [Abstract][Full Text] [Related]
7. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. Huo M; Zhao Y; Satterlee AB; Wang Y; Xu Y; Huang L J Control Release; 2017 Jan; 245():81-94. PubMed ID: 27863995 [TBL] [Abstract][Full Text] [Related]
8. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma. Zhao Q; Guo J; Wang G; Chu Y; Hu X Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489 [TBL] [Abstract][Full Text] [Related]
9. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients. Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B Front Immunol; 2020; 11():613215. PubMed ID: 33679700 [TBL] [Abstract][Full Text] [Related]
10. Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis. He Y; Hung SW; Liang B; Zhang R; Gao Y; Chu CY; Zhang T; Xu H; Chung JPW; Wang CC Front Immunol; 2021; 12():641206. PubMed ID: 34367125 [TBL] [Abstract][Full Text] [Related]
11. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Ko JS; Rayman P; Ireland J; Swaidani S; Li G; Bunting KD; Rini B; Finke JH; Cohen PA Cancer Res; 2010 May; 70(9):3526-36. PubMed ID: 20406969 [TBL] [Abstract][Full Text] [Related]
12. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042 [TBL] [Abstract][Full Text] [Related]